Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis

CASE: A 68-year-old female was diagnosed with giant cell tumor of bone (GCTB) metastatic to her lungs. The patient was treated with IV denosumab for the course of 4.5 years for these metastases. The metastatic tumor burden decreased significantly after only 3 months of therapy. The size of the metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Egbert, Ryan Carlisle, Folsom, Ryan, Bell, Jeff, Rajani, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442345/
https://www.ncbi.nlm.nih.gov/pubmed/28573059
http://dx.doi.org/10.1155/2017/2302597
_version_ 1783238391756750848
author Egbert, Ryan Carlisle
Folsom, Ryan
Bell, Jeff
Rajani, Rajiv
author_facet Egbert, Ryan Carlisle
Folsom, Ryan
Bell, Jeff
Rajani, Rajiv
author_sort Egbert, Ryan Carlisle
collection PubMed
description CASE: A 68-year-old female was diagnosed with giant cell tumor of bone (GCTB) metastatic to her lungs. The patient was treated with IV denosumab for the course of 4.5 years for these metastases. The metastatic tumor burden decreased significantly after only 3 months of therapy. The size of the metastases has been stable for over 4 years. CONCLUSION: Denosumab therapy has promise in the treatment of GCTB, including pulmonary metastasis. However, the long-term role of denosumab for pulmonary metastases is yet to be determined.
format Online
Article
Text
id pubmed-5442345
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-54423452017-06-01 Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis Egbert, Ryan Carlisle Folsom, Ryan Bell, Jeff Rajani, Rajiv Case Rep Orthop Case Report CASE: A 68-year-old female was diagnosed with giant cell tumor of bone (GCTB) metastatic to her lungs. The patient was treated with IV denosumab for the course of 4.5 years for these metastases. The metastatic tumor burden decreased significantly after only 3 months of therapy. The size of the metastases has been stable for over 4 years. CONCLUSION: Denosumab therapy has promise in the treatment of GCTB, including pulmonary metastasis. However, the long-term role of denosumab for pulmonary metastases is yet to be determined. Hindawi 2017 2017-05-10 /pmc/articles/PMC5442345/ /pubmed/28573059 http://dx.doi.org/10.1155/2017/2302597 Text en Copyright © 2017 Ryan Carlisle Egbert et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Egbert, Ryan Carlisle
Folsom, Ryan
Bell, Jeff
Rajani, Rajiv
Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
title Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
title_full Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
title_fullStr Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
title_full_unstemmed Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
title_short Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
title_sort denosumab therapy for giant cell tumor of bone pulmonary metastasis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442345/
https://www.ncbi.nlm.nih.gov/pubmed/28573059
http://dx.doi.org/10.1155/2017/2302597
work_keys_str_mv AT egbertryancarlisle denosumabtherapyforgiantcelltumorofbonepulmonarymetastasis
AT folsomryan denosumabtherapyforgiantcelltumorofbonepulmonarymetastasis
AT belljeff denosumabtherapyforgiantcelltumorofbonepulmonarymetastasis
AT rajanirajiv denosumabtherapyforgiantcelltumorofbonepulmonarymetastasis

Ejemplares similares